IKT
Inhibikase Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.50
−0.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 260.5K | 123.4K |
| Cost of Revenue | — | — | 26.3K | 13.6M | 6.7K |
| Gross Profit | — | — | (26.3K) | (13.4M) | 116.7K |
| Operating Expenses | |||||
| R&D Expense | 38.2M | 29.8M | 17.2M | 13.6M | 12.0M |
| SG&A Expense | 27.4M | 23.6M | 11.4M | 6.7M | 6.2M |
| General & Admin Expense | 7.7M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 149.3K | (1.4M) | (26.3K) | (13.6M) | — |
| Total Operating Expenses | 65.8M | 52.0M | 28.6M | 6.7M | 18.2M |
| Cost and Expenses | 65.8M | 52.0M | 28.6M | 20.4M | 18.3M |
| Operating Income (EBIT) | (65.8M) | (52.0M) | (28.6M) | (20.1M) | (18.1M) |
| Non-Operating | |||||
| Interest Income | 3.3M | 3.7M | 1.1M | 1.1M | 74.5K |
| Interest Expense | — | — | — | — | 74.5K |
| Net Interest Income | 3.3M | 3.7M | 1.1M | 1.1M | — |
| Other Non-Op Income/Expense | 5.2M | 3.7M | 1.1M | 1.1M | 74.5K |
| Non-Operating Income (excl Interest) | (3.4M) | 1.4M | (1.1M) | (1.1M) | (74.5K) |
| EBT (Pre-Tax Income) | (60.6M) | (48.3M) | (27.5M) | (19.0M) | (18.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (60.6M) | (48.3M) | (27.5M) | (19.0M) | (18.1M) |
| Earnings from Cont. Ops | (60.6M) | (48.3M) | (27.5M) | (19.0M) | (18.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (60.6M) | (48.3M) | (27.5M) | (19.0M) | (18.1M) |
| Per Share | |||||
| Basic EPS | ($0.48) | ($0.49) | ($1.16) | ($3.57) | ($4.26) |
| Diluted EPS | ($0.48) | ($0.49) | ($1.16) | ($3.57) | ($4.26) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.05 | $0.03 |
| Shares | |||||
| Basic Shares Outstanding | 174.6M | 98.3M | 23.7M | 5.3M | 4.2M |
| Diluted Shares Outstanding | 174.6M | 98.3M | 23.7M | 5.3M | 4.2M |
| Profitability Metrics | |||||
| EBITDA | (62.3M) | (53.3M) | (27.5M) | (18.9M) | (18.0M) |
| D&A | 23.7K | 60.5K | 26.3K | 177.4K | 6.7K |
| EBIT | (62.4M) | (53.3M) | (27.5M) | (19.0M) | (18.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026